Opin vísindi

Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial

Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial


Title: Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
Author: Malm, Carl Johan
Alfredsson, Joakim
Erlinge, David
Guðbjartsson, Tómas
Gunn, Jarmo
James, Stefan
Møller, Christian H
Nielsen, Susanne J
Sartipy, Ulrik
Tønnessen, Theis
... 1 more authors Show all authors
Date: 2023-05
Language: English
Scope: 8
Department: Faculty of Medicine
Other departments
Series: American Heart Journal; 259()
ISSN: 0002-8703
DOI: 10.1016/j.ahj.2023.01.011
Subject: Hjarta- og lungnaskurðlæknisfræði; Humans; Platelet Aggregation Inhibitors/therapeutic use; Ticagrelor/therapeutic use; Acute Coronary Syndrome/drug therapy; Prospective Studies; Aspirin/therapeutic use; Coronary Artery Bypass; Registries; Percutaneous Coronary Intervention; Treatment Outcome; Cardiology and Cardiovascular Medicine
URI: https://hdl.handle.net/20.500.11815/4147

Show full item record

Citation:

Malm , C J , Alfredsson , J , Erlinge , D , Guðbjartsson , T , Gunn , J , James , S , Møller , C H , Nielsen , S J , Sartipy , U , Tønnessen , T & Jeppsson , A 2023 , ' Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial ' , American Heart Journal , vol. 259 , pp. 1-8 . https://doi.org/10.1016/j.ahj.2023.01.011

Abstract:

The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-label, registry-based randomized trial with 1:1 randomization to dual antiplatelet therapy with ASA and ticagrelor or ASA only, in patients undergoing first isolated CABG, with a planned enrollment of 2200 patients at Nordic cardiac surgery centers. The primary efficacy end point is a composite of time to all-cause death, myocardial infarction, stroke, or new coronary revascularization within 12 months after randomization. The primary safety end point is time to hospitalization due to major bleeding. Secondary efficacy end points include time to the individual components of the primary end point, cardiovascular death, and rehospitalization due to cardiovascular causes. High-quality health care registries are used to assess primary and secondary end points. The patients will be followed for 10 years. The TACSI trial will give important information useful for guiding the antiplatelet strategy in acute coronary syndrome patients treated with CABG.

Description:

Funding Information: The trial is funded by Swedish Research Council (grant 2017-00495 to AJ), The Swedish Heart Lung Foundation (grants 2017-0459 to AJ; 2018-0560 to AJ, 2021-0433 to AJ) the Swedish state under an agreement between the Swedish government and the county councils concerning economic support of research and education of doctors (ALF agreement) (grants ALFGBG 925251 to AJ; ALFGBG 725131 to AJ; ALFGBG 966204 to AJ. There is no industrial involvement or support. Publisher Copyright: © 2023 The Authors

Files in this item

This item appears in the following Collection(s)